van der Vuurst de Vries, Roos M.
Mescheriakova, Julia Y.
Runia, Tessel F.
Siepman, Theodora A. M.
Wokke, Beatrijs H. A.
Samijn, Johnny P. A.
Hintzen, Rogier Q.
Funding for this research was provided by:
the Dutch MS research Foundation
Article History
Received: 15 December 2017
Revised: 29 January 2018
Accepted: 30 January 2018
First Online: 20 February 2018
Conflicts of interest
: Roos M. van der Vuurst de Vries—declares no conflict of interests. Julia Y. Mescheriakova—declares no conflict of interests. Tessel F. Runia—declares no conflict of interests. Theodora A. M. Siepman—declares no conflict of interests. Beatrijs H. A. Wokke—declares no conflict of interests. Johnny P. A. Samijn received honoraria for serving on advisory boards for Merck-Serono, Genzyme and Roche. And received travel Grants from Merck-Serono. He participated in trials with BiogenIdec, Merck-Serono, Roche and Genzyme, outside the submitted work. Rogier Q. Hintzen received honoraria for serving on advisory boards for Biogen Idec, Roche, Sanofi. He participated in trials with BiogenIdec, Merck-Serono, Roche, Genzyme and Novartis, outside the submitted work.
: This study was approved by the Medical Ethics Committee of Erasmus MC Rotterdam, the Netherlands.
: Written informed consent was obtained from all patients.